Bavarian Nordic bags $160M for priority review voucher

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review voucher (PRV) earned through the approval of its chikungunya vaccine, Vimkunya (chikungunya vaccine), marking one of the highest prices paid for a PRV in recent years.

The company said the deal, which remains subject to regulatory clearance, is expected to close in the third quarter of 2025. The PRV was granted by the American medicines regulator in February following approval of Vimkunya for individuals aged 12 and older under the FDA’s tropical disease program. The buyer has not been publicly identified.

Bavarian Nordic acquired the shot in 2023 as part of its $270 million purchase of Emergent BioSolutions’ travel health business. As the vaccine originated from research licensed by the US National Institutes of Health, NIH will receive 20% of the voucher’s gross proceeds.